What is IPI score lymphoma?

International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) Predicts overall and progression-free survival in DLBCL based on risk factors. Note: IPI results are included for historical comparisons only.

What does MIPI score mean?

Abstract. The Mantle Cell Lymphoma International Prognostic Index (MIPI) combines four factors to differentiate low-, intermediate- and high-risk prognostic groups in advanced mantle cell lymphoma using data from patients treated in clinical trials.

How is MIPI calculated?

The MIPI is calculated using the following formula: [0.03535 × age (years)] + 0.6978 (if ECOG > 1) + [1.367 × log10(LDH/ULN)] + [0.9393 × log10(white cells per uL blood)]. A score < 5.7 indicates low-risk disease, 5.7 – 6.2 indicates intermediate risk, and >= 6.2 high risk.

How is mantle cell lymphoma treated?

Although there is no standard of care for MCL, aggressive chemo-immunotherapy regimens containing rituximab and cytarabine, followed by consolidation with autologous stem cell transplantation and maintenance rituximab, are the most used approach in young fit patients, and chemo-immunotherapy, followed by rituximab …

What does Stage 3 lymphoma mean?

Stage 3. This means that you have lymphoma on both sides of the diaphragm. One example is that the lymphoma is in lymph nodes on both sides of the diaphragm. Another example (see below) is that the lymphoma is in lymph nodes above the diaphragm, as well as lymphoma in the spleen.

What is age adjusted IPI?

The age-adjusted IPI (aaIPI) comprises 3 factors (performance status, LDH, and stage) that also predict survival in de novo DLCL. 13. It has not been extensively evaluated as a prognostic tool in the relapsed/primary refractory setting.

What is R Maxi chop?

R-maxi-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) This treatment cycle is repeated every 21 days. You will have 3 cycles alternating with 3 cycles of R-HiDAC. Day.

How is mantle cell lymphoma staged?

Stage I: The cancer is in one lymph node or group of lymph nodes next to each other. Stage II: It’s in two or more lymph nodes or groups of lymph nodes next to each other. Stage III: It’s in lymph nodes on both sides of your diaphragm or nodes above your diaphragm and in your spleen. Stage IV: It’s widespread.

How long can a person live with mantle cell lymphoma?

Mantle Cell Lymphoma Prognosis The average life expectancy of patients with mantle cell lymphoma is about 6 to 7 years. The 10-year survival rate, that is, how many people will be alive 10 years after diagnosis, is only 5 to 10 percent.

Is mantle cell lymphoma always fatal?

Mantle cell lymphoma (MCL) is generally considered incurable. Many people with MCL go into remission after initial treatment. But in most cases, their condition relapses within a few years. Remission happens when the cancer comes back.

What is the difference between IPI and Flipi in MCL?

IPI and FLIPI showed poor separation of survival curves for MCL patients (6). The IPI score classifies most patients in the two intermediate-risk groups and does not separate the outcomes. The FLIPI score places most patients into the high-risk group and does not separate low from intermediate in outcome (7).

What does MIPI stand for?

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

What is the prognostic index for mantle cell lymphoma (MCL)?

In 2008, Hoster et aldeveloped the Mantle Cell Lymphoma International Prognostic Index (MIPI) as the first prognostic index specific to patients with advanced stage MCL (6). The prognostic index is based on four independent factors: age, performance status, lactate dehydrogenase (LDH) and leukocyte count.

How does the MIPI classify patients with multiple myeloma (MM)?

The MIPI is able to classify patients into three risk groups: low risk (median survival not reached after median 32 mos follow-up and 5-year OS rate of 60%), intermediate risk (median survival 51 months) and high risk (median survival 29 months).